Terns Pharmaceuticals (TERN)
(Delayed Data from NSDQ)
$7.81 USD
+0.35 (4.69%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $7.80 -0.01 (-0.13%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Terns Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 263 | 283 | 166 | 75 | 20 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 13 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 2 | 1 | 3 | 3 |
Total Current Assets | 267 | 285 | 167 | 91 | 22 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 1 |
Total Assets | 269 | 287 | 168 | 92 | 24 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 13 | 0 |
Accounts Payable | 3 | 2 | 2 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 6 | 5 | 9 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 12 | 8 | 7 | 23 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 1 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 13 | 10 | 8 | 24 | 6 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 186 | 96 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 588 | 520 | 343 | 15 | 0 |
Retained Earnings | -333 | -242 | -182 | -132 | -92 |
Other Equity | 0 | -1 | 0 | 0 | 14 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 255 | 277 | 160 | 69 | 18 |
Total Liabilities & Shareholder's Equity | 269 | 287 | 168 | 92 | 24 |
Total Common Equity | 255 | 277 | 160 | -117 | -78 |
Shares Outstanding | 61.80 | 53.70 | 25.20 | NA | NA |
Book Value Per Share | 4.13 | 5.16 | 6.36 | 0.00 | 0.00 |
Fiscal Year End for Terns Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 225 | 241 | 263 | 267 | 286 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 5 | 4 | 4 | 3 |
Total Current Assets | 230 | 246 | 267 | 270 | 288 |
Net Property & Equipment | 0 | 0 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 231 | 247 | 269 | 272 | 290 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 3 | 3 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 7 | 9 | 8 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 11 | 9 | 12 | 12 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 1 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 12 | 10 | 13 | 13 | 16 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 597 | 592 | 588 | 571 | 557 |
Retained Earnings | -378 | -355 | -333 | -312 | -282 |
Other Equity | 0 | 0 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 219 | 237 | 255 | 258 | 274 |
Total Liabilities & Shareholder's Equity | 231 | 247 | 269 | 272 | 290 |
Total Common Equity | 219 | 237 | 255 | 258 | 274 |
Shares Outstanding | 64.60 | 64.60 | 61.80 | 61.00 | 56.60 |
Book Value Per Share | 3.39 | 3.66 | 4.13 | 4.24 | 4.84 |